Skip to main navigation
Syndax
Main navigation
  • About
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • Back
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Back
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Back
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Back
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Back
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • FAQs
    • Contact Us
  • Join Us
Syndax
Contact Us
Main navigation
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • FAQs
    • Contact Us
  • Join Us

Investors

 

SEC Filing Details

Document Details

Form
SC 13G/A
Filing Date
Feb 14, 2023
Document Date
Feb 14, 2023
Form Description
An amendment to the SC 13G filing
Filing Group
Other
Company
Syndax Pharmaceuticals, Inc.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Shareholder Tools

  • Printed Materials
  • Downloads
  • Email Alerts
  • RSS
  • Print
  • Share
  • Search

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS
© 2023 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • News
  • Investors
  • Careers